About us


Visible science

Developing innovative ocular solutions

Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health. We aim to be a fully integrated ophthalmic pharmaceutical with a direct presence in the U.S and in the major European markets.

We will achieve our goal by advancing our product candidates through clinical development to approval in the U.S. and EU markets, optimizing their development and commercialization in the rest of the world through partnerships, and expanding our pipeline with new internal research and development projects, potential in-licensing or acquisitions of ophthalmic development candidates or approved products.

Our ophthalmic pipeline includes two programs in clinical development, NCX 470 targeting glaucoma and NCX 4251 targeting blepharitis. We also have two products which are commercialized in the U.S., VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.

We are focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases.

Disease focus areas

Leadership team

Nicox has a highly experienced leadership team. Their combined expertise, from leading pharmaceutical and biotech companies, covers research, clinical development, regulatory, finance, business and corporate development, alliance management and communication. Michele Garufi, one of Nicox’s co-founders, is Chairman and Chief Executive Officer.

Ophthalmic partnerships


Nicox entered into an exclusive license agreement with Eyevance Pharmaceuticals LLC for the commercialization of its product ZERVIATE® (cetirizine ophthalmic solution), 0.24% in the U.S. Eyevance Pharmaceuticals is a U.S. based company committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision and better quality of life for all patients.

Eyevance was acquired in September 2020 by Santen Holdings U.S. Inc., a subsidiary of Santen Pharmaceutical Co., Ltd of Japan, a global company focused exclusively on ophthalmology


Nicox has entered an exclusive license agreement with ITROM Pharmaceutical Group to develop and commercialize its product ZERVIATE® (cetirizine ophthalmic solution), 0.24% in the Gulf and Arab markets.

ITROM is a Dubai based pharmaceutical organization with over 20 years’ experience in the regional ophthalmological scene. The group maintains a unique focus on introducing breakthrough and innovative pharmaceutical products within the MENA region, with Ophthalmology and Women’s Health specialties placed at the forefront of its development activities.


Nicox has signed an exclusive license agreement with Laboratorios Grin for the registration and commercialization of ZERVIATE™ (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico.
Grin, a wholly-owned subsidiary of Lupin Limited, is a specialty pharmaceutical company, present in Mexico for over 50 years, engaged in the development, manufacturing and commercialization of branded ophthalmic products.

Grin is a leader in the ophthalmology segment, primarily in the therapeutic areas of allergic conjunctivitis, dry eye, glaucoma and post-cataract recovery, among others.


Nicox and Ocumension Therapeutics entered into exclusive license agreements for the development and commercialization of its product, ZERVIATE® (cetirizine ophthalmic solution), 0.24% and product candidates, NCX 470 and NCX 4251, for the Chinese market.

Ocumension Therapeutics is a China-based ophthalmology company, listed on Hong Kong Exchange, dedicated to identifying, developing and commercializing first or best-in-class ophthalmic therapies.


Nicox entered into an exclusive worldwide licensing agreement with Bausch + Lomb, a Bausch Health Companies Inc. company, which grants Bausch + Lomb exclusive worldwide rights to develop and market latanoprostene bunod, commercialized as VYZULTA® (latanoprostene bunod ophthalmic solution),0.024%.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better.

Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.


Nicox signed with Samil Pharmaceutical an exclusive license agreement for the development and commercialization of ZERVIATE® (ophthalmic solution of cetirizine), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea.

Samil Pharmaceutical, with 71 years of experience in the pharmaceutical industry, is considered as one of the leading Korean companies specialized in the field of ophthalmic medicines including the research and development of drugs in the field of ophthalmology

Click on a partner logo to read more
All information on partnerships signed by Nicox can be found in the section Overview of the activities of the Document Universel d’Enregistrement and the subsequent press releases.